Cancer cells are sensitive to wild-type IDH1 inhibition under nutrient limitation
A. Vaziri-Gohar, J. J. Hue, H. J. Graor, E. Prendergast, V. Chen, J. Cassel, F. S. Mohammed, A. Abbas, K. Dukleska, I. Khokhar, O. Hajhassani, M. Zarei, R. Wang, L. D. Rothermel, I. Bederman, , J. M. Winter
This study shows that wild-type IDH1 is a metabolic target in pancreatic cancer cells under nutrient limitation, and FDA-approved drugs can inhibit it effectively in preclinical models.
bioRxiv · Nov 19, 2020 · PreprintCancer Biology